These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 38943828)

  • 21. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
    Corona SP; Generali D
    Drug Des Devel Ther; 2018; 12():321-330. PubMed ID: 29497278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.
    Cetin B; Wabl CA; Gumusay O
    Future Oncol; 2022 Mar; 18(9):1143-1157. PubMed ID: 35137602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDK4/6 inhibitors: The Devil is in the Detail.
    Magge T; Rajendran S; Brufsky AM; Foldi J
    Curr Oncol Rep; 2024 Jun; 26(6):665-678. PubMed ID: 38713311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
    Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
    Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
    De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
    Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDK4/6 inhibitors in breast cancer - from
    Saleh L; Wilson C; Holen I
    Acta Oncol; 2020 Feb; 59(2):219-232. PubMed ID: 31671026
    [No Abstract]   [Full Text] [Related]  

  • 27. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
    Yang C; Li Z; Bhatt T; Dickler M; Giri D; Scaltriti M; Baselga J; Rosen N; Chandarlapaty S
    Oncogene; 2017 Apr; 36(16):2255-2264. PubMed ID: 27748766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
    Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
    Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies.
    Xu XQ; Pan XH; Wang TT; Wang J; Yang B; He QJ; Ding L
    Acta Pharmacol Sin; 2021 Feb; 42(2):171-178. PubMed ID: 32504067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials.
    Huang T; He Y; Yu C; Mao F; Si Y
    Endokrynol Pol; 2023; 74(1):89-105. PubMed ID: 36704980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent progress of CDK4/6 inhibitors' current practice in breast cancer.
    Wang X; Zhao S; Xin Q; Zhang Y; Wang K; Li M
    Cancer Gene Ther; 2024 Sep; 31(9):1283-1291. PubMed ID: 38409585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
    Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
    Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer.
    Talia M; Cirillo F; Scordamaglia D; Di Dio M; Zicarelli A; De Rosis S; Miglietta AM; Capalbo C; De Francesco EM; Belfiore A; Grande F; Rizzuti B; Occhiuzzi MA; Fortino G; Guzzo A; Greco G; Maggiolini M; Lappano R
    J Exp Clin Cancer Res; 2024 Jun; 43(1):171. PubMed ID: 38886784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Belli S; Esposito D; Ascione CM; Messina F; Napolitano F; Servetto A; De Angelis C; Bianco R; Formisano L
    Cancer Lett; 2024 Jul; 593():216968. PubMed ID: 38788968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
    Pla H; Felip E; Obadia V; Pernas S; Viñas G; Margelí M; Fort-Culillas R; Del Barco S; Sabaté N; Fort E; Lezcano C; Cirauqui B; Quiroga V; Stradella A; Gil Gil M; Esteve A; Recalde S
    Clin Transl Oncol; 2024 Jul; 26(7):1748-1758. PubMed ID: 38519708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
    O'Sullivan CC; Clarke R; Goetz MP; Robertson J
    JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.